Best of ASCO - 2014 Annual Meeting

 

Welcome

Germ Cell/Testicular

Genitourinary (Nonprostate) Cancer

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A single center experience of the impact of treatment-related toxicity in the clinical outcomes of elderly patients with metastatic germ cell tumors.

Anand Sharma

e16048

Adjuvant carboplatin for clinical stage I testicular seminoma in New Zealand centers: Retrospective analysis of efficacy and long-term adverse effects.

Elias Aris Chandran

e16041

Analysis of three models to predict pathohistology in patients undergoing postchemotherapy RPLND for (pcRPLND) advanced nonseminomatous germ cell tumors (NSGCT).

Axel Heidenreich

e16053

Biomarkers of outcomes in a randomized phase II trial of first-line paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for intermediate- and poor-risk germ cell tumors (GCT).

Darren R. Feldman

4563

Circulating tumor (ct)-DNA alterations in patients with testicular germ tumors.

Amin Nassar

e16063

Delivery of bleomycin among patients with testicular cancer: A population-based study of pulmonary monitoring and toxicity.

Christopher M. Booth

e16056

Health related quality of life analysis among testicular germ cell tumor survivors treated in a tertiary cancer hospital in India.

Abhishek Raj

e16057

High DNA damage levels to predict hematologic toxicity in testicular germ cell tumor (TGCT) patients treated with first-line chemotherapy.

Michal Mego

e16055

Impact of cannabis (CA) use on chemotherapy (C) treatment and tumor characteristics of patients (pts) with testicular germ cell tumor (TGCT): Experience of the Centre Léon Bérard (CLB).

Patrick Arnaud-Coffin

e16054

Impact of cisplatin-related adverse health outcomes (AHOs) on employment outcomes and self-reported health (SRH) among testicular cancer survivors (TCS).

Sarah L. Kerns

e16058

Improved outcomes in testicular germ cell tumor patients treated at the referral center in Slovakia in the last decade.

Michal Chovanec

e16059

Long-term sexual impairment in relationship with metabolic health in testicular germ-cell tumor survivors.

Michal Chovanec

e16060

Management of stage I seminomatous germ-cell cancer (SGCC): Results from 4 different risk-adapted strategies in a single institution.

Mariona Riudavets

e16047

Outcome of patients with stage 2 or stage 3 seminoma treated with 3 cycles of cisplatin-etoposide chemotherapy (EP120): Updated data from a single center retrospective study.

Claudia Gardiner

e16061

Phase II study of avelumab in multiple relapsed/refractory testicular germ cell cancer.

Michal Mego

e16045

Prognostic value of serum tumor marker (STM) rate of decline during high-dose chemotherapy (HDCT) and peripheral-blood stem-cell transplant (PBSCT) for relapsed germ-cell tumors (rGCT).

Nabil Adra

e16044

Risk factors for renal failure (RF) during high-dose chemotherapy (HDCT) and outcomes for patients (pts) with relapsed germ-cell tumors (rGCT).

Kevin Juan Zhang

e16042

Site, age, and gender distribution of extra-gonadal germ cell tumors in the US from 1973 to 2015.

Elizabeth Pan

e16051

The clinical features of extragonadal germ cell tumors: A SEER analysis.

Yanal Mufeed Alnimer

e16064

Utilization of mental health services among survivors of testicular cancer: A population-based study.

Christopher M. Booth

e16062